TY - JOUR
T1 - Factors affecting IgG4-mediated complement activation
AU - Oskam, Nienke
AU - Damelang, Timon
AU - Streutker, Marij
AU - Ooijevaar-de Heer, Pleuni
AU - Nouta, Jan
AU - Koeleman, Carolien
AU - Van Coillie, Julie
AU - Wuhrer, Manfred
AU - Vidarsson, Gestur
AU - Rispens, Theo
N1 - Publisher Copyright:
Copyright © 2023 Oskam, Damelang, Streutker, Ooijevaar-de Heer, Nouta, Koeleman, Van Coillie, Wuhrer, Vidarsson and Rispens.
PY - 2023/1/26
Y1 - 2023/1/26
N2 - Of the four human immunoglobulin G (IgG) subclasses, IgG4 is considered the least inflammatory, in part because it poorly activates the complement system. Regardless, in IgG4 related disease (IgG4-RD) and in autoimmune disorders with high levels of IgG4 autoantibodies, the presence of these antibodies has been linked to consumption and deposition of complement components. This apparent paradox suggests that conditions may exist, potentially reminiscent of in vivo deposits, that allow for complement activation by IgG4. Furthermore, it is currently unclear how variable glycosylation and Fab arm exchange may influence the ability of IgG4 to activate complement. Here, we used well-defined, glyco-engineered monoclonal preparations of IgG4 and determined their ability to activate complement in a controlled system. We show that IgG4 can activate complement only at high antigen and antibody concentrations, via the classical pathway. Moreover, elevated or reduced Fc galactosylation enhanced or diminished complement activation, respectively, with no apparent contribution from the lectin pathway. Fab glycans slightly reduced complement activation. Lastly, we show that bispecific, monovalent IgG4 resulting from Fab arm exchange is a less potent activator of complement than monospecific IgG4. Taken together, these results imply that involvement of IgG4-mediated complement activation in pathology is possible but unlikely.
AB - Of the four human immunoglobulin G (IgG) subclasses, IgG4 is considered the least inflammatory, in part because it poorly activates the complement system. Regardless, in IgG4 related disease (IgG4-RD) and in autoimmune disorders with high levels of IgG4 autoantibodies, the presence of these antibodies has been linked to consumption and deposition of complement components. This apparent paradox suggests that conditions may exist, potentially reminiscent of in vivo deposits, that allow for complement activation by IgG4. Furthermore, it is currently unclear how variable glycosylation and Fab arm exchange may influence the ability of IgG4 to activate complement. Here, we used well-defined, glyco-engineered monoclonal preparations of IgG4 and determined their ability to activate complement in a controlled system. We show that IgG4 can activate complement only at high antigen and antibody concentrations, via the classical pathway. Moreover, elevated or reduced Fc galactosylation enhanced or diminished complement activation, respectively, with no apparent contribution from the lectin pathway. Fab glycans slightly reduced complement activation. Lastly, we show that bispecific, monovalent IgG4 resulting from Fab arm exchange is a less potent activator of complement than monospecific IgG4. Taken together, these results imply that involvement of IgG4-mediated complement activation in pathology is possible but unlikely.
KW - antibodies
KW - complement activation
KW - fab arm exchange
KW - glycoengineering
KW - IgG4-related disease
KW - primary membranous nephropathy
UR - http://www.scopus.com/inward/record.url?scp=85147778739&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1087532
DO - 10.3389/fimmu.2023.1087532
M3 - Article
C2 - 36776883
AN - SCOPUS:85147778739
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1087532
ER -